Boipai Payal, Sinha Tulika, Kumari Shiwani, Kumari Pooja, Sharma Apoorwa, Trivedi Kiran
Obstetrics and Gynecology, Rajendra Institute of Medical Sciences, Ranchi, IND.
Obstetrics and Gynecology, Bharti Vidyapeeth Medical College, Pune, IND.
Cureus. 2024 Oct 16;16(10):e71632. doi: 10.7759/cureus.71632. eCollection 2024 Oct.
Objective This study sought to evaluate the safety and efficacy of mifepristone as a uterine sensitizer in shortening induction to delivery time in term pregnancy. Study design A prospective study was carried out on primigravida with a singleton term pregnancy, cephalic presentation, 37 to 41 weeks gestation, Bishop score ≤6, and consented to the study. A total of 116 participants were divided into two groups by random computer-generated sequence. On admission, the Bishop score was assessed. Group A (n=58) received 200 mg of mifepristone. Group B (n=58) received a placebo orally. In both groups, a post-intervention assessment was done after 24 hours, intracervical dinoprostone gel was administered with a maximum of three doses, six hours apart, if the Bishop score was ≤6. The primary outcome was to evaluate the effectiveness of oral mifepristone based on Bishop score improvement, the need for dinoprostone gel, and induction to delivery time. The secondary outcome was to evaluate the safety of oral mifepristone based on cesarean section rate and fetomaternal outcome. Results The Bishop score markedly improved in group A after 24 hours of intervention. A total of 31 women delivered vaginally after receiving only mifepristone. Mean induction to delivery time significantly improved in group A at 23.22±12.57 hours as compared to that in group B at 38.79±7.32 hours. Cesarean delivery rate was lower in group A (27.59%) compared to group B (44.83%). Birth outcomes were consistent in both groups with no neonatal mortality. Conclusion Oral mifepristone has proved as a promising agent as a uterine sensitizer in inducing labor as it has significantly decreased induction to delivery time.
目的 本研究旨在评估米非司酮作为子宫致敏剂在缩短足月妊娠引产至分娩时间方面的安全性和有效性。
研究设计 对单胎足月妊娠、头先露、妊娠37至41周、Bishop评分≤6且同意参与研究的初产妇进行了一项前瞻性研究。通过计算机随机生成序列将116名参与者分为两组。入院时评估Bishop评分。A组(n = 58)接受200mg米非司酮。B组(n = 58)口服安慰剂。两组在干预24小时后进行干预后评估,如果Bishop评分≤6,则给予宫颈内米索前列醇凝胶,最大剂量为三剂,间隔6小时。主要结局是根据Bishop评分改善情况、米索前列醇凝胶的需求以及引产至分娩时间来评估口服米非司酮的有效性。次要结局是根据剖宫产率和母婴结局评估口服米非司酮的安全性。
结果 干预24小时后,A组的Bishop评分显著改善。共有31名妇女仅接受米非司酮后经阴道分娩。A组的平均引产至分娩时间显著缩短,为23.22±12.57小时,而B组为38.79±7.32小时。A组的剖宫产率(27.59%)低于B组(44.83%)。两组的出生结局一致,无新生儿死亡。
结论口服米非司酮已被证明是一种有前景的子宫致敏剂,可用于引产,因为它显著缩短了引产至分娩的时间。